Literature DB >> 12757707

Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1.

Hung-Kai Chen1, Pedro Fernandez-Funez, Summer F Acevedo, Yung C Lam, Michael D Kaytor, Michael H Fernandez, Alastair Aitken, Efthimios M C Skoulakis, Harry T Orr, Juan Botas, Huda Y Zoghbi.   

Abstract

Spinocerebellar ataxia type 1 (SCA1) is one of several neurological disorders caused by a CAG repeat expansion. In SCA1, this expansion produces an abnormally long polyglutamine tract in the protein ataxin-1. Mutant polyglutamine proteins accumulate in neurons, inducing neurodegeneration, but the mechanism underlying this accumulation has been unclear. We have discovered that the 14-3-3 protein, a multifunctional regulatory molecule, mediates the neurotoxicity of ataxin-1 by binding to and stabilizing ataxin-1, thereby slowing its normal degradation. The association of ataxin-1 with 14-3-3 is regulated by Akt phosphorylation, and in a Drosophila model of SCA1, both 14-3-3 and Akt modulate neurodegeneration. Our finding that phosphatidylinositol 3-kinase/Akt signaling and 14-3-3 cooperate to modulate the neurotoxicity of ataxin-1 provides insight into SCA1 pathogenesis and identifies potential targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12757707     DOI: 10.1016/s0092-8674(03)00349-0

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  131 in total

Review 1.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

Review 2.  Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes.

Authors:  Carol Mackintosh
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

3.  Inefficient degradation of truncated polyglutamine proteins by the proteasome.

Authors:  Carina I Holmberg; Kristine E Staniszewski; Kwame N Mensah; Andreas Matouschek; Richard I Morimoto
Journal:  EMBO J       Date:  2004-10-07       Impact factor: 11.598

Review 4.  Polyglutamine neurodegeneration: expanded glutamines enhance native functions.

Authors:  Harry T Orr
Journal:  Curr Opin Genet Dev       Date:  2012-01-25       Impact factor: 5.578

5.  Reduction of protein kinase A-mediated phosphorylation of ATXN1-S776 in Purkinje cells delays onset of Ataxia in a SCA1 mouse model.

Authors:  Judit M Pérez Ortiz; Nissa Mollema; Nicholas Toker; Carolyn J Adamski; Brennon O'Callaghan; Lisa Duvick; Jillian Friedrich; Michael A Walters; Jessica Strasser; Jon E Hawkinson; Huda Y Zoghbi; Christine Henzler; Harry T Orr; Sarita Lagalwar
Journal:  Neurobiol Dis       Date:  2018-05-11       Impact factor: 5.996

Review 6.  Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1.

Authors:  Huda Y Zoghbi; Harry T Orr
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

7.  Serine 421 regulates mutant huntingtin toxicity and clearance in mice.

Authors:  Ian H Kratter; Hengameh Zahed; Alice Lau; Andrey S Tsvetkov; Aaron C Daub; Kurt F Weiberth; Xiaofeng Gu; Frédéric Saudou; Sandrine Humbert; X William Yang; Alex Osmand; Joan S Steffan; Eliezer Masliah; Steven Finkbeiner
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

8.  RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1.

Authors:  Megan S Keiser; James C Geoghegan; Ryan L Boudreau; Kim A Lennox; Beverly L Davidson
Journal:  Neurobiol Dis       Date:  2013-04-10       Impact factor: 5.996

9.  14-3-3 Epsilon antagonizes FoxO to control growth, apoptosis and longevity in Drosophila.

Authors:  Mette Damgaard Nielsen; Xi Luo; Benoît Biteau; Keith Syverson; Heinrich Jasper
Journal:  Aging Cell       Date:  2008-07-28       Impact factor: 9.304

10.  Exploring prion protein biology in flies: genetics and beyond.

Authors:  Diego E Rincon-Limas; Sergio Casas-Tinto; Pedro Fernandez-Funez
Journal:  Prion       Date:  2010-01-30       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.